The adoption of nintedanib in systemic sclerosis: the SENSCIS study

The adoption of nintedanib in systemic sclerosis: the SENSCIS study

Bibliographic Details
Main Authors:	Teresa Bruni, Francesco Varone
Format:	Article
Language:	English
Published:	European Respiratory Society 2020-06-01
Series:	Breathe
Online Access:	http://breathe.ersjournals.com/content/16/2/200005.full

Similar Items

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
by: Alves, M., et al.
Published: (2022)

Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity
by: Maurizio Cutolo, et al.
Published: (2021-08-01)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
by: Jaume Bordas-Martinez, et al.
Published: (2021-01-01)

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease
by: Toshiyuki Sumi, et al.
Published: (2021-03-01)

Nintedanib in NSCLC: evidence to date and place in therapy
by: Giuseppe Bronte, et al.
Published: (2016-05-01)

Nintedanib-Induced Renal Thrombotic Microangiopathy
by: Takeshi Fujita, et al.
Published: (2021-07-01)

Nintedanib in the treatment of idiopathic pulmonary fibrosis
by: Mariano E. Mazzei, et al.
Published: (2015-06-01)

Is nintedanib effective for idiopathic pulmonary fibrosis?
by: Alejandro Jeldres
Published: (2017-06-01)

Focus on Nintedanib in NSCLC and other tumors
by: Anna Manzo, et al.
Published: (2016-12-01)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
by: Mouhamad Nasser, et al.
Published: (2021-10-01)

Effects of Nintedanib in an Animal Model of Liver Fibrosis
by: Lutz Wollin, et al.
Published: (2020-01-01)

[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]
by: Andrea Belisari, et al.
Published: (2017-04-01)

The Effect of Nintedanib on T-Cell Activation, Subsets and Functions
by: Ubieta K, et al.
Published: (2021-03-01)

Galectin-3 levels are elevated following nintedanib treatment
by: Gali Epstein Shochet, et al.
Published: (2020-11-01)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
by: Antoniu Sabina A
Published: (2012-11-01)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
by: Hee-Young Yoon, et al.
Published: (2018-10-01)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
by: Lin T, et al.
Published: (2017-04-01)

Nintedanib: A novel therapeutic agent for pulmonary fibrosis
by: Arpita Singh, et al.
Published: (2015-01-01)

Profile of nintedanib in the treatment of solid tumors: the evidence to date
by: Awasthi N, et al.
Published: (2015-12-01)

The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
by: Grzegorz Grześk, et al.
Published: (2021-12-01)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
by: Luca Richeldi, et al.
Published: (2020-01-01)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
by: Ryosuke Imai, et al.
Published: (2020-03-01)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
by: Christopher J. Ryerson, et al.
Published: (2019-04-01)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
by: Yoko Ito, et al.
Published: (2019-01-01)

Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
by: Reck M, et al.
Published: (2015-07-01)

Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
by: Hiroaki Ogata, et al.
Published: (2021-05-01)

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
by: Vincent Cottin, et al.
Published: (2021-03-01)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
by: Ian Glaspole, et al.
Published: (2021-04-01)

Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis.
by: Masahiro Nemoto, et al.
Published: (2021-01-01)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
by: Manon Belhassen, et al.
Published: (2021-05-01)

Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis
by: Yusuke Ochi, et al.
Published: (2020-10-01)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
by: Claudia Valenzuela, et al.
Published: (2020-01-01)

Clinical development of nintedanib for advanced non-small-cell lung cancer
by: Takeda M, et al.
Published: (2015-11-01)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
by: Jai B Mullerpattan, et al.
Published: (2019-01-01)

Nintedanib in non-small cell lung cancer: from preclinical to approval
by: Christian Caglevic, et al.
Published: (2015-08-01)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
by: Bonella F, et al.
Published: (2015-12-01)

A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib
by: Tamaki Kakuwa, et al.
Published: (2019-01-01)

A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
by: Liu H, et al.
Published: (2018-12-01)

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
by: Abe M, et al.
Published: (2018-10-01)

Effect of nintedanib thermo-sensitive hydrogel on neovascularization in alkali burn rat model
by: Yan Gong, et al.
Published: (2020-06-01)